Topical treatment for scalp psoriasis: Comparison of patient preference, quality of life and efficacy for non-alcoholic mometasone emulsion versus calcipotriol/betamethasone gel in daily clinical practice.
OBJECTIVE
To evaluate patients' assessment of therapy, efficacy, quality of life and treatment adherence in patients with scalp psoriasis treated with non-alcoholic mometasone emulsion or calcipotriol/betamethasone gel.


METHODS
Prospective, open-label, multicentre, non-interventional study. Patients with non-severe scalp psoriasis were treated with mometasone emulsion or calcipotriol/betamethasone gel. Evaluations included patient's global assessment of treatment, physician's global assessment of disease severity, quality of life (Dermatology Life Quality Index), physician's subjective evaluation of therapy, treatment adherence and adverse events.


RESULTS
Ninety-five patients treated with mometasone emulsion and 88 treated with calcipotriol/betamethasone gel were included in the intention-to-treat analysis. Patients' global assessment of treatment favoured mometasone emulsion over calcipotriol/betamethasone gel (p = 0.008), with treatment rated as good/very good by 91% versus 82.5%. Patients were less likely to report irritation of fingers' skin with mometasone than with calcipotriol/betamethasone (p = 0.0015). Severity of scalp psoriasis and quality of life improved in both groups. Adherence to treatment was similar in both groups. Physicians' perception of efficacy, tolerability and compliance was better for mometasone emulsion.


CONCLUSIONS
Non-alcoholic mometasone emulsion achieved greater acceptability to patients and physicians than calcipotriol/betamethasone gel for the treatment of scalp psoriasis. Both topical treatments were similarly effective in terms of disease severity and quality of life.
a Department of Dermatology , Universitat de Barcelona, Hospital Clínic , Barcelona , Spain and.
Adrià
A
Gual
a Department of Dermatology , Universitat de Barcelona, Hospital Clínic , Barcelona , Spain and.
Ignasi
I
Pau-Charles
b Department of Dermatology and Allergy , Ludwig Maximilian University , Munich , Germany.
Sonja
S
Molin
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001623:Betamethasone / Q000627:therapeutic use*; D002117:Calcitriol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D004338:Drug Combinations; D004655:Emulsions; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate / Q000627:therapeutic use*; D010342:Patient Acceptance of Health Care; D010349:Patient Compliance; D057240:Patient Preference / Q000706:statistics & numerical data*; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy* / Q000523:psychology; D011788:Quality of Life / Q000523:psychology*; D012536:Scalp Dermatoses / Q000188:drug therapy* / Q000523:psychology
D003879:Dermatologic Agents; D004338:Drug Combinations; D004655:Emulsions; D005938:Glucocorticoids; D000068656:Mometasone Furoate; C055085:calcipotriene; D001623:Betamethasone; D002117:Calcitriol
Calcipotriol/betamethasone gel; mometasone emulsion; scalp psoriasis; topical treatments